

Plans to Evaluate Recommendations for Booster Doses of Yellow Fever Vaccine

Joseph A. Bocchini, Jr., M.D.
ACIP, Workgroup Chair

**Japanese Encephalitis and Yellow Fever
Vaccines Workgroup**

October 24, 2013

Yellow fever (YF) vaccine in the U.S.

- ❑ Live-attenuated YF vaccine (YF-VAX®) is the only YF vaccine licensed for use in U.S.**
- ❑ Vaccine recommended for people residing in or traveling to YF endemic areas**
- ❑ In accordance with International Health Regulations, ACIP recommends a booster dose every 10 years**
- ❑ ACIP recommendations for use of YF vaccine were updated in 2009 and published in 2010**

WHO Strategic Advisory Group of Experts (SAGE) Recommendations for YF Vaccine

- In April 2013, based on systematic evidence review, SAGE concluded:**
 - Single dose of YF vaccine sufficient to confer sustained immunity and lifelong protection against YF disease**
 - Booster doses of YF vaccine are not needed**
- Countries can still require YF vaccine booster doses under International Health Regulations**

JE and YF Vaccine Workgroup: Plans

- ❑ Restructure JE Vaccine Workgroup to form JE and YF Vaccines Workgroup**
- ❑ Review long-term immunogenicity and vaccine failure data for YF vaccine**
- ❑ Develop recommendations regarding YF vaccine booster doses in U.S. travelers and laboratory workers**
- ❑ Anticipate ACIP vote on YF vaccine booster dose in 2014**

JE and YF Vaccines Workgroup Members

ACIP members

Joseph Bocchini (Chair)

Lorry Rubin

Liaison representatives

Cody Meissner (AAP)

Robert Schechter (AIM)

CDC Leads

Erin Staples (NCEZID/DVBD)

Marc Fischer (NCEZID/DVBD)

Ex Officio members

Doran Fink (FDA)

Jesse Geibe (DoD)

Michael Holbrook (NIH)

Lewis Markoff (FDA)

Pat Repik (NIH)

Invited consultants

Elizabeth Barnett

Alan Barrett

Lin Chen

David Shlim